Evidence map›Paper›PMID 34851124›Full record

ArticleMolecular pharmaceutics2022

Studies on the Vitrified and Cryomilled Bosentan.

Aldona Minecka, Krzysztof Chmiel, Karolina Jurkiewicz, Barbara Hachuła, Rafał Łunio, Daniel Żakowiecki, Kinga Hyla, Bartłomiej Milanowski, Kajetan Koperwas, Kamil Kamiński and 2 more

Open access · hybridAbstract read
In one paragraph

Article in Molecular pharmaceutics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.4field-weighted citation impact, top 49% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 1 country.

Aldona MineckaDepartment of Pharmacognosy and Phytochemistry, Faculty of Pharmaceutical Sciences in Sosnowiec, Medical University of Silesia in Katowice, ul. Jagiellonska 4, 41-200 Sosnowiec, Poland.ORCID 0000-0001-5603-032X
Krzysztof ChmielDepartment of Pharmacognosy and Phytochemistry, Faculty of Pharmaceutical Sciences in Sosnowiec, Medical University of Silesia in Katowice, ul. Jagiellonska 4, 41-200 Sosnowiec, Poland.ORCID 0000-0003-4532-0051
Karolina JurkiewiczInstitute of Physics, Faculty of Science and Technology, University of Silesia in Katowice, 75 Pułku Piechoty 1, 41-500 Chorzów, Poland.ORCID 0000-0002-4289-7827
Barbara HachułaInstitute of Chemistry, University of Silesia in Katowice, 40-006 Katowice, Poland.ORCID 0000-0001-9886-1076
Rafał ŁunioPolpharma SA, 83-200 Starogard Gdański, Poland.
Daniel ŻakowieckiChemische Fabrik Budenheim KG, Rheinstrasse 27, 55257 Budenheim, Germany.
Kinga HylaChair and Department of Pharmaceutical Technology, Faculty of Pharmacy, Poznan University of Medical Sciences, 60-780 Poznan, Poland.
Bartłomiej MilanowskiChair and Department of Pharmaceutical Technology, Faculty of Pharmacy, Poznan University of Medical Sciences, 60-780 Poznan, Poland.ORCID 0000-0002-6450-174X
Kajetan KoperwasInstitute of Physics, Faculty of Science and Technology, University of Silesia in Katowice, 75 Pułku Piechoty 1, 41-500 Chorzów, Poland.
Kamil KamińskiInstitute of Physics, Faculty of Science and Technology, University of Silesia in Katowice, 75 Pułku Piechoty 1, 41-500 Chorzów, Poland.ORCID 0000-0002-5871-0203
Marian PaluchInstitute of Physics, Faculty of Science and Technology, University of Silesia in Katowice, 75 Pułku Piechoty 1, 41-500 Chorzów, Poland.
Ewa KamińskaDepartment of Pharmacognosy and Phytochemistry, Faculty of Pharmaceutical Sciences in Sosnowiec, Medical University of Silesia in Katowice, ul. Jagiellonska 4, 41-200 Sosnowiec, Poland.ORCID 0000-0001-9725-8654
Institute of Physics · PLMedical University of Silesia · PLPoznan University of Medical Sciences · PLUniversity of Silesia in Katowice · PL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In this paper, several experimental techniques [X-ray diffraction, differential scanning calorimetry (DSC), thermogravimetry, Fourier transform infrared spectroscopy, and broad-band dielectric spectroscopy] have been applied to characterize the structural and thermal properties, H-bonding pattern, and molecular dynamics of amorphous bosentan (BOS) obtained by vitrification and cryomilling of the monohydrate crystalline form of this drug. Samples prepared by these two methods were found to be similar with regard to their internal structure, H-bonding scheme, and structural (α) dynamics in the supercooled liquid state. However, based on the analysis of α-relaxation times (dielectric measurements) predicted for temperatures below the glass-transition temperature (

Indexed as

BosentanCalorimetry, Differential ScanningDielectric SpectroscopyDrug LiberationSpectroscopy, Fourier Transform InfraredThermogravimetryVitrificationX-Ray DiffractionBosentanbosentancryomillingdissolution ratemolecular mobilityvitrificationwater removal

Identifiers

PMID34851124
PMCPMC8728735
OpenAlexW3215528535

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.